Aspirin-triggered lipoxins (ATLs) are specialized pro-resolving mediators (SPMs) produced when low-dose aspirin permanently acetylates COX-2 at serine-530, converting this enzyme from a prostaglandin factory into a 15R-HETE producer. Leukocyte 5-lipoxygenase then converts 15R-HETE into 15-epi-lipoxin A4 (15-epi-LXA4), an SPM that actively terminates inflammation by stopping neutrophil recruitment, enhancing macrophage efferocytosis, and suppressing pro-inflammatory gene transcription.
Think of COX-2 as a factory switchboard operator. Normally, this operator routes incoming arachidonic acid calls to the "prostaglandin production line" β making inflammatory mediators like PGE2. When low-dose aspirin arrives, it's like someone permanently flipping one switch on the operator's board (acetylating serine-530). Now when arachidonic acid calls come in, they get routed to a completely different department: the 15R-HETE line. This product then gets picked up by a second factory down the street (5-lipoxygenase in leukocytes) and turned into aspirin-triggered lipoxins β molecules that actively clean up the inflammatory mess. High-dose aspirin, by contrast, shuts down the entire switchboard (blocks all COX-2 activity), stopping both inflammation AND resolution. Low-dose aspirin is surgical: it doesn't turn the factory off, it just rewires it to make cleanup crews instead of alarm signals. This explains why 50mg aspirin can be anti-inflammatory while 500mg can delay healing.
The synthesis of aspirin-triggered lipoxins involves a two-cell, two-enzyme process that requires aspirin's irreversible modification of COX-2:
graph TD
A[Arachidonic Acid] -->|Aspirin-acetylated COX-2| B[15R-HETE]
B -->|5-Lipoxygenase in leukocytes| C[15-epi-LXA4]
C -->|Binds| D[ALX/FPR2 Receptor]
D --> E["Neutrophils: β Chemotaxis"]
D --> F["Macrophages: β Efferocytosis"]
D --> G["Epithelium: β Permeability"]
D --> H["β NF-ΞΊB activation"]
H --> I["β Pro-inflammatory gene transcription"]
C -->|Resistant to| J[Enzymatic degradation by 15-PGDH]
K[High-dose Aspirin] -.->|Blocks COX-2 completely| L[No SPM production]
M[Low-dose Aspirin 50-100mg] -->|Acetylates Ser-530| N[COX-2 produces 15R-HETE]
Step-by-step cascade:
- COX-2 acetylation: Aspirin (acetylsalicylic acid) irreversibly transfers an acetyl group to serine-530 of COX-2 enzyme
- Substrate switching: Acetylated COX-2 loses ability to produce PGH2 (prostaglandin precursor) but gains ability to convert arachidonic acid to 15R-HETE instead of the usual 15S-HETE
- Transcellular biosynthesis: 15R-HETE is released and taken up by adjacent leukocytes (neutrophils, monocytes, eosinophils)
- 5-LOX conversion: Leukocyte 5-lipoxygenase (5-LO) converts 15R-HETE β 5(6)-epi-15-epi-LXA4 β 15-epi-LXA4 (aspirin-triggered lipoxin A4)
- Receptor binding: 15-epi-LXA4 binds ALX/FPR2 receptor (also called FPRL1) with high affinity (Kd ~0.4 nM)
- Cellular effects:
- Neutrophils: ALX/FPR2 activation β Gi protein coupling β β cAMP β β integrin expression β β chemotaxis and transendothelial migration
- Macrophages: ALX/FPR2 β β phagocytic capacity β β recognition of "eat-me" signals (phosphatidylserine) on apoptotic cells β enhanced efferocytosis without inflammatory mediator release
- Endothelium: β vascular permeability via enhanced VE-cadherin junction stability
- Gene regulation: ALX/FPR2 signaling β β NF-ΞΊB nuclear translocation β β transcription of IL-1Ξ², TNF-Ξ±, IL-6, COX-2 genes
- Metabolic stability: 15-epi-LXA4 has R-configuration at C15 (vs. S-configuration in natural LXA4), making it resistant to 15-hydroxyprostaglandin dehydrogenase (15-PGDH) degradation β extends half-life compared to natural lipoxins
Key enzymatic parameters:
- Optimal aspirin dose for ATL production: 50-100 mg/day (acetylates ~50-70% of COX-2)
- COX-2 acetylation is irreversible; new protein synthesis required to restore prostaglandin production
- 5-LOX requires FLAP (5-lipoxygenase activating protein) and CaΒ²βΊ for activity
- ATL production peaks 4-6 hours post-aspirin ingestion (coincides with maximal COX-2 acetylation in vascular endothelium)
Aspirin-triggered lipoxins represent a paradigm shift in understanding aspirin's therapeutic mechanism beyond simple cyclooxygenase inhibition. This reveals aspirin as a resolution pharmacology agent rather than merely an anti-inflammatory drug.
Clinical applications:
-
Cardiovascular disease prevention: Traditional explanation focused on aspirin's antiplatelet effect (via COX-1 inhibition β β thromboxane A2). ATL production provides additional mechanism: β endothelial activation, β leukocyte adhesion, β atherosclerotic plaque stabilization via enhanced macrophage efferocytosis of apoptotic foam cells. Patients with low SPM production capacity show reduced cardiovascular benefit from aspirin.
-
Hormetic dosing principle: Demonstrates Metamodel 5 (hormesis) in action. Low-dose aspirin (50-100mg) enables pro-resolving pathway; high-dose (300-500mg) blocks both inflammation AND resolution, potentially delaying wound healing and tissue repair. Clinical implication: use lowest effective dose for chronic inflammatory conditions.
-
Chronic inflammatory disease: Patients with chronic inflammation often show deficient resolution capacity. ATL production can restore resolution in:
- Inflammatory bowel disease: β intestinal neutrophil infiltration, β mucosal healing
- Periodontal disease: β bone loss, β tissue regeneration
- Rheumatoid arthritis: β synovial inflammation, β joint destruction
-
Omega-3 synergy: omega-3 fatty acids (EPA/DHA) + aspirin produces additional SPM classes (aspirin-triggered resolvins, aspirin-triggered protectins). This explains clinical observation that fish oil + low-dose aspirin shows greater anti-inflammatory benefit than either alone. Requires adequate substrate: omega-3 index >8% for optimal ATL production.
-
Resolution deficiency phenotype: Some patients have genetic polymorphisms in 5-LOX or ALX/FPR2 that reduce ATL synthesis or responsiveness. These individuals may show poor response to aspirin therapy and require alternative SPM-based approaches.
-
Selfish immune system: ATLs shift immune priorities from "defend at all costs" (neutrophil-driven inflammation) to "clean up and restore" (macrophage-driven resolution). This represents immune system reallocation toward tissue preservation rather than pathogen elimination β relevant when chronic inflammation exceeds pathogen threat.
Clinical thresholds:
- Plasma 15-epi-LXA4 levels: <50 pg/mL indicates resolution insufficiency
- Optimal aspirin dosing: 50-100 mg/day (higher doses suppress ATL production)
- Time to peak effect: 4-6 hours post-ingestion
- Requires arachidonic acid substrate: plasma AA <100 ΞΌg/mL may limit ATL production
Intervention framework:
- Assess omega-6:omega-3 ratio (target 3:1 to 1:1 for optimal substrate availability)
- Low-dose aspirin 50-75mg daily (evening dosing may maximize vascular COX-2 acetylation)
- Ensure adequate arachidonic acid intake (not zero β need substrate for SPM synthesis)
- Address resolution pathway deficiencies (vitamin D, specialized pro-resolving mediator supplementation)
- Monitor resolution biomarkers: CRP decline rate, neutrophil-lymphocyte ratio normalization
- 15-epi-LXA4 differs from natural LXA4 only in stereochemistry at C15 position (R vs. S configuration)
- R-configuration makes ATLs 10-fold more resistant to enzymatic degradation than natural lipoxins
- Aspirin's acetylation of COX-2 is irreversible β enzyme remains modified for its entire lifespan (~8-12 hours in endothelial cells)
- ATL production requires transcellular biosynthesis: COX-2 (endothelial/epithelial cells) + 5-LOX (leukocytes)
- Optimal aspirin dose 50-100mg/day β doses >300mg inhibit both inflammation and resolution
- ALX/FPR2 receptor binds both natural lipoxins and aspirin-triggered lipoxins with similar affinity (Kd ~0.4-0.5 nM)
- ATLs reduce neutrophil recruitment by 60-80% in experimental inflammation models
- Enhance macrophage efferocytosis by 2-3 fold (measured as apoptotic cell uptake per macrophage)
- Anti-fibrotic effects mediated via β TGF-Ξ² signaling and β myofibroblast differentiation
- Evening aspirin dosing may optimize ATL production (COX-2 expression peaks at night in vascular tissue)
- Genetic polymorphisms in 5-LOX (promoter variants) reduce ATL synthesis capacity in ~30% of population
- ATL plasma half-life: 15-20 minutes (vs. 5-8 minutes for natural LXA4)
- Production requires adequate arachidonic acid substrate but NOT excessive omega-6 intake
- Synergy with EPA/DHA: combined therapy produces aspirin-triggered resolvins (AT-RvD1, AT-RvE1)
- aspirin β low-dose aspirin irreversibly acetylates COX-2 to trigger ATL production via substrate switching
- COX-2 β acetylation at serine-530 converts COX-2 from prostaglandin producer to 15R-HETE producer
- COX-2 acetylation β mechanism by which aspirin enables SPM synthesis instead of blocking all eicosanoid production
- 5-LOX β leukocyte 5-lipoxygenase performs second enzymatic step converting 15R-HETE to 15-epi-LXA4
- arachidonic acid β substrate required for ATL synthesis; optimal plasma levels 100-200 ΞΌg/mL
- specialized pro-resolving mediators β ATLs are founding members of SPM family that actively resolve inflammation
- lipoxins β ATLs are aspirin-triggered structural analogs of natural lipoxin A4 with enhanced metabolic stability
- ALX-FPR2 receptor β G-protein coupled receptor that mediates all ATL cellular effects on neutrophils, macrophages, epithelium
- neutrophils β ATLs bind ALX/FPR2 to decrease neutrophil chemotaxis, transmigration, and tissue infiltration
- macrophages β ATLs enhance macrophage phagocytosis of apoptotic cells (efferocytosis) without triggering inflammatory mediator release
- efferocytosis β ATLs upregulate "eat-me" signal recognition and phagocytic capacity in macrophages for non-inflammatory clearance
- resolution of inflammation β ATLs are pro-resolving mediators that actively drive inflammation termination and tissue restoration
- vascular permeability β ATLs reduce endothelial permeability by stabilizing VE-cadherin junctions
- NF-ΞΊB β ATLs suppress NF-ΞΊB nuclear translocation to inhibit transcription of IL-1Ξ², TNF-Ξ±, IL-6, COX-2
- cardiovascular disease β ATLs contribute to aspirin's cardioprotective effects beyond antiplatelet action via endothelial protection
- hormesis β ATL production exemplifies hormetic dose-response: low aspirin doses enable resolution, high doses block it
- omega-3 fatty acids β EPA/DHA work synergistically with aspirin to produce additional SPM classes (aspirin-triggered resolvins)
- chronic inflammation β ATLs help terminate chronic inflammatory states by shifting immune function from attack to cleanup
- wound healing β ATLs promote non-fibrotic wound healing via anti-fibrotic effects and enhanced tissue remodeling
- atherosclerosis β ATLs stabilize atherosclerotic plaques by enhancing macrophage efferocytosis of apoptotic foam cells
- inflammatory bowel disease β ATLs reduce intestinal inflammation and promote mucosal healing in experimental colitis models
- 15-LOX β endothelial 15-lipoxygenase produces natural lipoxins from arachidonic acid without aspirin requirement
- 12-LOX β platelet 12-lipoxygenase can also contribute to transcellular lipoxin biosynthesis
- prostaglandins β ATL synthesis occurs when COX-2 is reprogrammed away from prostaglandin production
- Resolution Pharmacology β ATLs represent first example of pharmaceutical induction of endogenous pro-resolving mediators
- Resoleomics β ATL measurement is key biomarker in resolution profiling to assess inflammation resolution capacity
- fibrosis β ATLs prevent excessive collagen deposition and myofibroblast activation during tissue repair
- endothelial dysfunction β ATLs protect endothelial barrier function and reduce leukocyte adhesion molecule expression
- TGF-beta β ATLs suppress TGF-Ξ² signaling to prevent fibrotic responses during inflammation resolution
- platelet activation β while aspirin inhibits platelet COX-1 (antiplatelet effect), ATLs provide additional anti-thrombotic mechanisms